{"disease":{"id":"low-hdl-cholesterol","name":"low hdl cholesterol"},"drugs":{"marketed":[{"drug_id":"lopid","indication_name":"Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04236518","title":"Nutritional Transitions to More Plant Proteins and Less Animal Proteins: Understanding the Induced Metabolic Reorientations and Searching for Their Biomarkers (ProVegOmics)","phase":"NA","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}